Proteostasis Therapeutics Культура компании

Ms. Meenu Chhabra has been the Chief Executive Officer and President at Proteostasis Therapeutics, Inc. since June 30, 2014. Ms. Chhabra's initial focus is driving the development of Proteostasis' cystic fibrosis franchise while leveraging its platform to identify pipeline appropriate assets addressing orphan and neurodegenerative disease indications. She has extensive managerial experience in the biopharmaceutical industry with a strong track record of corporate execution. Prior to joining Proteostasis, Ms. Chhabra served as the Chief Executive Officer and President of Allozyne Inc. since September 2007. While at Allozyne, she implemented a strategy to maximize the value of the proprietary platform by building a portfolio of risk reward balanced product candidates including antibody drug conjugates. Ms. Chhabra served as the Chief Business Officer of BioXell S.p.A. since January 24, 2006. She served as Vice President, Business Development and Licensing for Novartis Consumer Health (Geneva, Switzerland) and Novartis AG. Ms. Chhabra joined BioXell in September 2003 as Director of Business Development and Commercial Strategy. Prior to BioXell, Ms. Chhabra held various sales, marketing and business development positions in major pharmaceutical companies (most notably, Bristol Myers Squibb Inc., Parke Davis/Warner Lambert and Fresenius Kabi AG). Previously, Ms. Chhabra served as Business Development Manager at MCR Research Inc. Prior to joining MCR, she served as a Business Development Manager at Fresenius Kabi Healthcare. She has been a Director of Allozyne, Inc. since October 2007 and Proteostasis Therapeutics, Inc. since June 30, 2014. Ms. Chhabra holds a Bachelor of Science degree from University of Toronto in Pharmacology and Master's in Business Administration from York University with a focus in Strategy and Finance.

Ms. Helen M. Boudreau has been Chief Financial Officer and Treasurer of Proteostasis Therapeutics, Inc. since July 25, 2017. Ms. Boudreau served as the Chief Financial Officer of FORMA Therapeutics, Inc. since October 2014 until June 2, 2017. Ms. Boudreau joined Forma with over 25 years global experience in finance, strategy and operations within the pharmaceutical, commercial banking and consumer sectors. Ms. Boudreau was responsible for US Treasury, Tax and Risk Management operations, financial management for all Corporate entities, as well as Investor Relations for US and Canada at Novartis. She joined Novartis in 2008 as Vice President, Investor Relations and was the Global Chief Financial Officer for Novartis Oncology, where she was responsible for Finance, IT, Strategic Sourcing, Innovation, Quality & Productivity until January 2012. From September 2008 to September 2014, Ms. Boudreau worked at Novartis Corporation, the U.S. corporate arm of Novartis AG , including served as the Chief Financial Officer of Novartis Corporation from November 2012 to September 2014, Vice President of Investor Relations from January 2012 to December 2012 and Vice President and Chief Financial Officer for Novartis Oncology from September 2008 to January 2012. She was responsible for North America. Prior to joining Novartis, she spent nearly 10 years at Pfizer Inc., where she served as Vice President, Finance for the Customer Business Unit and Commercial Operations. She was Vice President of Finance, Research and Development and the Senior Director of Financial Planning & Analysis at Pfizer, Inc. Previously at Pfizer, she spent eight years in R&D in roles of increasing responsibility for Global R&D Finance, Research Finance and Procurement, Financial Planning & Strategic Analysis and Strategic Management. She also worked in Strategic Planning in the restaurant division of PepsiCo/YUM Brands and as an Engagement Manager and Consultant at McKinsey & Co. She started her career in commercial and retail banking at Bank of America. She has been a Director of Proteostasis Therapeutics, Inc., since February 10, 2016. She has a BA in Economics, summa cum laude from the University of Maryland and an MBA with honors from the Darden School of Business at the University of Virginia.

Dr. Benito Munoz, also known as Ben, Ph.D. has been Chief Scientific Officer at Proteostasis Therapeutics, Inc., since March 2017 and served as its Senior Vice President of Drug Discovery since December 2015. Dr. Munoz is responsible for all of the Proteostasis' drug discovery research activities and operations. He is also responsible for expanding the pipeline with new drug candidates by managing activities related to hit identification, lead optimisation, drug candidate selection and all related aspects of chemistry, manufacturing and controls. He serves as the Director of Molecular Libraries Probe Centers Network (MLPCN) and Infectious Disease Initiative at the Broad Institute, Cambridge, MA. Dr. Munoz served as a Member of Scientific Advisory Board at Karyopharm Therapeutics, Inc. He is highly regarded medicinal chemist with over 15 years of drug discovery experience in the pharmaceutical and biotechnology industry; proven track record of leading drug discovery project teams, delivering preclinical, clinical candidates and targets for central nervous system (CNS) diseases, oncology and infectious disease. He also serves as the medicinal chemistry consultant to the Cancer Target Discovery and Development (CTD2) Network at the Broad Institute. Dr. Munoz received his Ph.D. from the University of Toronto and his postdoctoral training from the Scripps Institute in La Jolla, CA.

Dr. Po-Shun Lee, MD., has been Chief Medical Officer and Executive Vice President at Proteostasis Therapeutics, Inc. since June 2015 and December 2015 respectively and served as its Vice President of Clinical Development from December 3, 2014 to June 2015. Dr. Lee was a Founding Scientist of Critical Biologics Corporation. He focuses on leading the strategic selection process of which of the proprietary PTI CFTR compounds should proceed to clinical development, as part of its leading program in cystic fibrosis. Dr. Lee is a pulmonary and critical care physician with extensive experience in biopharmaceutical research and development in both the industry and academia. He has clinical and managerial drug development expertise. Dr. Lee was the Translational Medicine Expert that led the cystic fibrosis and asthma programs from early development to proof of concept at the Novartis Institute for Biomedical Research. Dr. Lee served as an Associate Medical Director of Vertex, where he supported Kalydeco registration and led a CFTR corrector program to positive proof of concept. Dr. Lee was a Physician-Scientist at Brigham Women's Hospital at Harvard Medical School, where he was the scientific founder of two biotech companies, Critical Biologics Corporation and BioAegis Therapeutics. He served as a Principal Investigator in the Pulmonary and Translational Medicine Units, Medical Director of the Pulmonary Function Lab, an attending physician in the Medical Intensive Care Unit and Instructor of Medicine at Harvard Medical School. Dr. Lee's academic research interests included endogenous inflammation control, aberrant cellular proliferation in rare lung diseases and gene therapy for cystic fibrosis. Dr. Lee holds a BA from Johns Hopkins University and MD from University of Pennsylvania.

Mr. Brett R. Hagen was Principal Accounting Officer and Vice President of Finance at Proteostasis Therapeutics, Inc. till December 2017. Mr. Hagen served as Principal Financial Officer and Controller of Proteostasis Therapeutics, Inc. since March 8, 2017 and May 2016 respectively. Mr. Hagen served as Interim Treasurer of Proteostasis Therapeutics, Inc. since February 10, 2017 and served as its Interim Chief Financial Officer from February 10, 2017 to March 8, 2017. He served as a Controller for BIND Therapeutics, Inc. He served as Vice President of Finance/Segment Controller of Boston Private Financial Holdings. He served as Manager of SEC Financial Reporting and Technical Account of The Princeton Review. He served as Controller of BioProcessors Corporation. He held a number of positions at PricewaterhouseCoopers LLP. Mr. Hagen received a B.A. from University of Minnesota, a Master in Accountancy from Wright State University and a M.S. in Finance from Suffolk University.

Magnus Ivarsson serves as the Vice President Translational Science of Proteostasis Therapeutics, Inc.. Magnus started at Proteostasis Therapeutics, Inc. in November of 2013. Magnus currently resides in the Greater Boston Area.

Marija Zecevic serves as the Chief Commercial Officer of Proteostasis Therapeutics, Inc.. Marija started at Proteostasis Therapeutics, Inc. in February of 2019. Marija currently resides in the Greater Boston Area.

Geoff Gilmartin serves as the Chief Development Officer of Proteostasis Therapeutics, Inc.. Geoff started at Proteostasis Therapeutics, Inc. in August of 2016. Geoff currently resides in the Greater Boston Area.

Sheila Gilbride-Wilson serves as the Chief Operating Officer of Proteostasis Therapeutics, Inc.. Sheila started at Proteostasis Therapeutics, Inc. in February of 2019. Sheila currently resides in the United States.